Cancer Therapy and Mitochondria

How Tumours Exploit Mitochondria, How Chemotherapy and Radiotherapy Affect Them, and What Recovery May Involve

Mitochondria make most of a cell's energy, but they also control cell death, oxidant signalling and calcium handling, which is why cancer treatment so often reaches them. They are often called the powerhouses of the cell, and the label is fair as far as it goes. Across their folded inner membrane, the respiratory chain passes electrons from fuel-derived molecules to oxygen and uses the energy released to build a membrane potential, which drives ATP synthesis, a process called oxidative phosphorylation. Mitochondria also generate reactive oxygen species (ROS) that act as signals, and they start the cascade that ends in apoptosis, the cell's built-in route to self-destruction.⁶,¹⁰

Two further features matter for cancer treatment. First, mitochondria carry their own small genome, mitochondrial DNA (mtDNA), which encodes essential subunits of the respiratory chain and sits close to where most cellular oxidants are made. Second, cells remodel their mitochondria constantly. Mitochondria fuse, divide, and are selectively cleared when damaged, a process called mitophagy.⁶ New ones are built through biogenesis, in which the regulator PGC-1α plays a central part.⁴ Healthy tissue relies on this cycle to clear damaged organelles and keep ATP supply matched to demand.

Tissues with high and constant energy demand, namely heart, skeletal muscle, nerve and brain, depend on this system most heavily, so they are often first to show strain when mitochondria are stressed. That helps explain why cancer treatment so often appears as fatigue, weakness, neuropathy or cardiac symptoms.

How do cancer cells exploit mitochondria?

Cancer cells exploit mitochondria in four main ways: they rewire their metabolism, use mitochondrial ROS as a signal to spread, consume oxygen and resist treatment, and reshape the immune and stromal cells around them. To understand why treatment reaches mitochondria, it helps to see why tumours depend on them. A 2026 review from researchers at the University of Santiago de Compostela and the German Cancer Research Center concluded that mitochondria coordinate metabolic and signalling pathways across multiple stages of cancer. They sustain proliferation, facilitate metastasis and shape the interaction between tumour and immune cells.¹

How cancer cells rewire mitochondrial metabolism

In the 1920s, Otto Warburg observed that tumours convert glucose to lactate even when oxygen is plentiful. For decades this was read as a sign of faulty mitochondria. The modern picture is more nuanced. A 2025 review in Signal Transduction and Targeted Therapy describes how metabolic reprogramming lets cancer cells exploit aerobic glycolysis, glutamine metabolism and altered lipid handling to support growth, survival and treatment resistance. The same review notes that mitochondrial dysfunction in tumours is highly heterogeneous, so no single pattern describes every cancer.²

Many tumour cells still lean heavily on respiration. When researchers at the Medical College of Wisconsin and Aix-Marseille University tested MitoQ, a mitochondria-targeted form of coenzyme Q10, in breast cancer and glioma cells, they found that it stopped cell proliferation at very low (sub-micromolar) concentrations. It also blocked oxygen consumption by complex I, the first enzyme of the respiratory chain. They concluded that inhibition of oxidative phosphorylation explained the antiproliferative effect.¹¹ An earlier study from the same Wisconsin group found that Mito-Q and a related compound, Mito-CP, synergised with the glycolysis inhibitor 2-deoxyglucose to lower ATP in two breast cancer cell lines. With time, however, energy function and colony-forming (clonogenic) survival were largely restored in some cells, a reminder that tumour cells adapt.¹²

How mitochondrial ROS drive cancer metastasis

Cancer cells also exploit the signalling side of mitochondria. Researchers at UCLouvain in Brussels proposed that mitochondria act as metabolic sensors of the tumour microenvironment. In their model, stressed cancer cells raise mitochondrial superoxide, which sets off a signalling chain (src, TGF-β and the kinase Pyk2) that primes metastatic progenitor cells for migration, invasion and colony formation.⁷ A small, controlled mitochondrial ROS signal can therefore help a tumour cell leave. In pancreatic cancer cells, the same group found that MitoQ at 100 to 500 nM selectively repressed the respiration of mesenchymal cells, lowered PGC-1α, NRF1 and electron transport chain expression, and reduced mitochondrial superoxide. It also cut the metastatic homing of human cells to mouse lungs by about 50%.¹³

Tumour hypoxia, radioresistance and chemotherapy resistance

Oxygen is a resource that tumours consume. Because oxygen stabilises radiation-induced DNA damage, hypoxic (low-oxygen) tumours are radioresistant. Mathematical modelling had predicted that inhibiting cancer-cell respiration would raise tumour oxygenation more effectively than trying to increase oxygen delivery.¹⁴ Mitochondria also decide whether a damaged cell dies. A 2025 review of colorectal cancer concluded that targeting mitochondrial metabolism, apoptosis, dynamics, mitophagy and intercellular transfer could overcome chemoresistance and restore treatment sensitivity in laboratory models. Key mechanisms included reversal of the Warburg effect and reactivation of intrinsic apoptosis.¹⁵

Hypoxia that comes and goes is particularly troublesome. Researchers at the University of Torino studied 28 human non-small cell lung cancer lines and found that intermittent hypoxia impaired the electron transport chain and reduced oxygen consumption, raising mitochondrial ROS. Through the low-oxygen signalling protein HIF-1α and the transcription factor C/EBP-β, this switched on drug-efflux pumps that pushed cisplatin and docetaxel out of the cells. It also reduced killing by Vγ9Vδ2 T cells, a type of immune cell. In 60 patients given cisplatin-based chemotherapy, the C/EBP-β isoform involved was abundant in hypoxic tumours and was associated with a lower response to treatment and shorter survival.¹⁶

Surviving cells are not always inert. Researchers at Houston Methodist and MD Anderson Cancer Center have described how some senescent cells induced by chemotherapy, which have stopped dividing, can re-enter the cell cycle and acquire stem-like properties.⁸

Mitochondria in the tumour microenvironment and immune cells

Tumours recruit mitochondria beyond their own cells. Mitochondria shape T-cell survival and function, macrophage polarisation, natural killer cell cytotoxicity and neutrophil activation, and they mediate the behaviour of stromal cells such as cancer-associated fibroblasts and tumour endothelial cells.² Dysfunctional mitochondria in CD8+ T cells within the tumour microenvironment can promote cancer progression.¹⁷

Tumour strategy What cancer cells do Why it matters for treatment
Metabolic rewiring Use glycolysis, glutamine, lipids and, often, oxidative phosphorylation.2,11 Dependence varies, so responses to mitochondria-targeted agents vary
ROS signalling Use subcytotoxic mitochondrial ROS to prime migration and invasion.7 ROS are signals as well as damage; blanket antioxidant effects are hard to predict
Oxygen use Respiration consumes oxygen and sustains hypoxia.14 Hypoxic tumours resist radiotherapy
Death evasion and adaptation Adapt mitochondrial metabolism, dynamics and apoptosis signalling. Intermittent hypoxia raises mitochondrial ROS and drug efflux.2,15,16 Chemoresistance; surviving cells may re-enter the cell cycle.8
Microenvironment control Alter mitochondrial function in immune and stromal cells.1,2,17 Shapes immune response and treatment outcome

How Does Chemotherapy Affect Mitochondrial Function?

Chemotherapy can disrupt mitochondrial redox balance, DNA, energy production and quality control, with effects that vary by drug, dose and tissue. It is not one treatment: anthracyclines such as doxorubicin, platinum drugs, taxanes, vinca alkaloids and proteasome inhibitors act in different ways, yet several mitochondrial effects recur.

Redox disruption: when signalling becomes damage

In a review of the clinical implications, researchers at Houston Methodist and MD Anderson Cancer Center concluded that cancer therapeutics trigger toxicity primarily by damaging mitochondria and raising mitochondrial ROS. This leads to damage to mtDNA and telomeric DNA and to DNA damage responses.⁸ Doxorubicin shows how this unfolds. Researchers at the University of Colorado Boulder found that four weeks after a single dose in mice, endothelium-dependent dilation in carotid arteries was 55% lower than in sham-treated animals. Vascular mitochondrial ROS was 52% higher, and mitochondrial superoxide dismutase (SOD2), an antioxidant enzyme, was 70% lower.¹⁸ Less antioxidant defence, more ROS and more injury form a feed-forward loop.

mtDNA and energy supply in high-demand cells

A review of the preclinical evidence on chemotherapy-induced peripheral neuropathy describes mtDNA adducts with cisplatin and oxaliplatin, opening of the mitochondrial permeability transition pore by paclitaxel, and altered mitochondrial calcium handling with vincristine and bortezomib.¹⁹ Nerve, heart and muscle are the most exposed.

What human muscle biopsies show

Human data are scarcer, and nearly all of it comes from women with breast cancer giving thigh-muscle (vastus lateralis) biopsies.

  • 11 women, before and after full treatment. At the University of Strasbourg and the Institut de Cancérologie Strasbourg Europe, biopsies taken before the first and after the last cycle of anthracycline–cyclophosphamide and taxane-based chemotherapy showed citrate synthase protein down 52% and VDAC down 38%, both markers of mitochondrial quantity. PGC-1α1, a regulator of biogenesis, fell 29.5%, and the fusion protein MFN2 fell 33.4%.⁴

  • 20 women, four days after a single dose. A follow-up study after one epirubicin–cyclophosphamide dose found muscle fibre cross-sectional area down 25%, complex I-linked respiratory capacity down 32% and citrate synthase down 53%.²⁰

  • 5 women, four days after first paclitaxel. With no prior chemotherapy: 18% fewer intermyofibrillar mitochondria, 34% more damaged mitochondria, a 29% fall in complex I-linked respiration, lower MFN2 and Fis1, and higher apoptosis. Overall oxidative phosphorylation capacity was unchanged.²¹

  • 13 women against 12 controls. Researchers at the University of Vermont found smaller muscle fibres and less mitochondrial content in women receiving adjuvant chemotherapy.²²

These studies are small, and they cannot fully separate chemotherapy from inactivity, nutrition or the cancer itself. Taken together, they suggest that fewer, damaged or less well-maintained mitochondria may be an early consequence of treatment.

Quality control and senescence: why effects may outlast treatment

A 2026 review from Gansu University of Chinese Medicine proposes that a disrupted mitochondrial quality-control network may be a unifying mechanism of chemotherapy-induced multi-organ toxicity.³ A separate 2026 review places the same network at the centre of chemotherapy-related cognitive impairment, often called chemo brain.²³ Treatment-induced senescence has been proposed to contribute to chronic vascular dysfunction, but whether it explains persistent symptoms in people remains a hypothesis.⁸

How Does Radiotherapy Affect Mitochondria?

Radiotherapy is usually described as nuclear DNA damage, but mitochondria both amplify and respond to the radiation signal. A 2026 review from West China Hospital, Sichuan University, describes mitochondria as the primary source of ROS and a key target of ROS attack during radiotherapy. Radiation can damage respiratory chain complexes and promote sustained mitochondrial ROS, while antioxidant systems mount a compensatory response, and the balance between the two helps determine cell fate.⁵

Damaged mitochondria also send messages. mtDNA, ATP and cytochrome c released from stressed mitochondria act as danger signals that help dendritic cells mature and promote antitumour immunity.⁵ In a space-radiation model, researchers at the Institute of Modern Physics, Chinese Academy of Sciences, found that iron-ion irradiation raised ROS in mouse brain and impaired mitochondrial respiration. It also altered mitochondrial dynamics and released cytochrome c, followed by apoptosis.²⁴ On the tumour side, mitochondrial function is closely linked to radioresistance, which is why mitochondria are being studied as radiosensitisation targets.⁵,²⁵

What Does Treatment-Related Mitochondrial Stress Look Like in the Clinic?

No symptom is specific to mitochondrial dysfunction. What helps is the pattern: high-demand tissues are affected, symptoms worsen with exertion, and onset follows a treatment exposure. Cancer-related fatigue illustrates the problem. In a review of the literature, LaVoy and colleagues noted that it may persist for years after treatment. Chronic inflammation, autonomic imbalance, dysfunction of the stress-hormone (HPA) axis and mitochondrial damage are among the candidate contributors.⁹

Presentation Proposed mitochondrial contribution Other causes to consider Evidence status
Persistent fatigue Reduced ATP-generating capacity, oxidative stress, altered muscle mitochondria.4,9 Anaemia, sleep disruption, endocrine dysfunction, pain, mood, deconditioning, infection, medicines Plausible; multifactorial
Exercise intolerance, weakness Lower mitochondrial content and respiratory capacity in muscle during chemotherapy.4,20,22 Cardiopulmonary limitation, muscle loss, anaemia, corticosteroids Small human biopsy studies
Peripheral neuropathy Axonal bioenergetic failure, mtDNA adducts, calcium dysregulation.19 Cumulative dose, diabetes, nutritional deficiency, other neuropathies Mechanistic
Cognitive change (chemo brain) Impaired mitochondrial quality control with neuroinflammation.23,26 Sleep, mood, endocrine therapy, vascular factors Review-level and preclinical
Cardiovascular dysfunction Mitochondrial ROS, lower SOD2, endothelial dysfunction.18,27 Cumulative dose, pre-existing disease, other cardiotoxic treatments Strong animal and mechanistic data

Cachexia, a wasting syndrome with loss of muscle and weight, is a distinct, multifactorial condition in which inflammation and mitochondrial oxidative stress are leading candidates among several drivers. It should not be reduced to a mitochondrial problem.²⁸

What Can Practitioners Measure, and What Supports Recovery?

No validated clinical test confirms treatment-related mitochondrial dysfunction, and individualised exercise is the best-supported recovery strategy.⁹ The sections below cover what can be measured and what may help.

How treatment-related mitochondrial dysfunction is assessed

Oxidative damage markers such as F2-isoprostanes and 8-OHdG describe net oxidation but not its source,²⁹,³⁰ and muscle biopsy markers such as citrate synthase and respirometry remain research tools.⁴ In practice, treatment history, standard pathology and functional outcomes guide the picture.

How mitochondria may recover

Recovery is not simply the reversal of damage. The quality-control framework in the 2026 chemo brain review involves several processes that must be restored. These are removal of damaged mitochondria through mitophagy, rebuilding of content through biogenesis, rebalancing of fusion and fission, and proteostasis (protein quality control).²³ These processes probably differ between muscle, nerve and brain, and how completely they recover is not known.

Supporting recovery

The best-supported intervention is individualised exercise, which is among the more successful treatments for cancer-related fatigue.⁹ In a colon-26 cachexia model, researchers found that moderate exercise in mice given oxaliplatin and 5-fluorouracil counteracted the loss of muscle mass and strength and partly rescued autophagy and mitochondrial function. However, exercise worsened survival in late-stage cachexia, a reminder that dose and disease stage matter.³¹ Programmes should reflect cardiac status, neuropathy, bone health and current cancer status. Reviewing medicines and addressing sleep, pain, nutrition and comorbidities target recognised drivers of fatigue whatever the mitochondrial contribution.

Mitochondria-directed drugs remain investigational. In the same model, the cardiolipin-targeting compound SS-31 restored intracellular ATP and prevented mitochondrial loss at day 21, but its effect on weight loss was transient.³² The chemo brain review lists mitochondria-targeted antioxidants, biogenesis activators and mitophagy modulators as candidates, with the aim of preserving cognition without compromising anticancer efficacy.²³

Here the central tension returns as a recovery paradox. Tumour mitochondrial heterogeneity and adaptive resistance complicate any intervention,² so supporting mitochondria in healthy tissue is not the same as supporting them everywhere.

What Does the Evidence Show?

Tumours rewire and exploit mitochondria in several ways.¹,² Chemotherapy and radiotherapy disturb mitochondrial function in preclinical models,³,⁵,⁸ and muscle biopsies from women receiving chemotherapy show lower mitochondrial content.⁴,²⁰ It is not yet clear which mitochondrial changes persist after treatment, or whether they drive symptoms or merely accompany them.

Most mechanistic data come from cell and animal models at doses and time courses that differ from clinical practice, and the first human biopsy study involved only 11 patients.⁴ Because tumour and normal-tissue mitochondria adapt differently, benefit in one cannot be assumed to be neutral in the other.² To our knowledge, no controlled human trial has yet tested a mitochondria-targeted drug for recovery after cancer treatment, which is where the field needs to go next.

How Is Mitoquinol Relevant to Treatment-Related Mitochondrial Stress?

Mitoquinol, called MitoQ in the studies described below, has shown protective and tumour-modifying effects in cell and animal models, with one two-patient report in thyroid cancer. To our knowledge, it has not yet been tested in controlled studies of people receiving or recovering from cancer treatment.Mitochondrial ROS sit at the centre of anthracycline vascular injury and of the radiation response, which makes a mitochondria-targeted compound a logical research tool. MitoQ Mitoquinol joins the quinone of coenzyme Q to a lipophilic triphenylphosphonium cation, a design intended to accumulate it within mitochondria.³³ In humans, Mitoquinol has been studied for vascular function in older adults and for exercise-induced DNA damage.³⁴,³⁵ The cancer studies also show that MitoQ does not act only as an antioxidant. Depending on concentration and context, it can inhibit respiration.¹¹,¹⁴ Researchers at UNIST in South Korea also identified it as an inhibitor of the mitochondrial chaperone TRAP1, with anticancer activity in vitro and in vivo.³⁶

Key Mitoquinol studies in cancer-treatment settings

In every study below, MitoQ was tested in cells or animals, apart from the two-patient report.

Setting What researchers found
Doxorubicin and arteries (mice) Researchers at the University of Colorado Boulder found that oral MitoQ for four weeks after doxorubicin prevented the fall in endothelium-dependent dilation (97% versus 42% with doxorubicin alone) by limiting mitochondrial ROS. Added to isolated arteries, MitoQ also restored function.18 The outcome was vascular, not tumour growth.
Doxorubicin and endothelial cells At the University of Utah, MitoQ cotreatment of human endothelial cells reduced mitochondrial ROS, DNA damage, telomere dysfunction and senescence markers, and preserved mitochondrial mass.37
Chemotherapy and muscle (myotubes, with patient biopsies) At the University of Vermont, doxorubicin and paclitaxel caused myosin loss, mitochondrial loss and higher ROS in mouse myotubes, and concurrent MitoQ prevented all three. In biopsies from 13 women on adjuvant chemotherapy, lower mitochondrial content was associated with smaller muscle fibres. MitoQ was tested only in the myotubes, and the patient data are cross-sectional.22
Cancer cachexia (mice) At Indiana University, MitoQ at 25 mg/kg in drinking water improved body weight loss, muscle mass and strength in colon-26 tumour-bearing mice without changing tumour size. It partly corrected the atrophy genes Atrogin-1 and MuRF1, but anabolic signalling was unchanged, and among mitochondrial markers only mitofusin-2 changed significantly.38
Radiosensitisation of hypoxic tumours (mice) At UCLouvain and University Hospital Zurich, nanomolar MitoQ abolished oxygen consumption in several human cancer cell lines. In mice, pretreating hypoxic MDA-MB-231 breast tumours delayed growth with single-dose and fractionated radiotherapy, whereas oxygenated MCF7 tumours were not radiosensitised. MitoTEMPO and SKQ1 did not share the effect.14
Normal-tissue radioprotection (cells, mice) At the Institute of Modern Physics in Lanzhou, MitoQ induced an AMPK-linked autophagy response in normal cells that protected them from radiation without reducing tumour-cell killing, and it protected against iron-ion brain injury in mice.24,39 The proposed mechanism, a pseudo-membrane potential,40 was challenged in a 2018 letter from Moscow State University, which found that triphenylphosphonium cations dissipated membrane potential and that autophagy tracked uncoupling.41
Radiation-induced blood toxicity (mice) At Massachusetts General Hospital, mice lacking the gene IEX-1 developed raised ROS and low platelet counts (thrombocytopenia) after radiation. MitoQ reversed the disorder, reduced ROS in megakaryocytes and platelets, and normalised platelet membrane potential and superoxide. This was a genetically susceptible model, not a standard radiotherapy setting.42
Recurrence after surgery (mice) In mice carrying human breast cancer (xenografts), the UCLouvain group reported that oral MitoQ, started after tumour take, did not slow primary tumour growth but largely prevented local recurrence after tumour removal and reduced lung metastases. MitoQ did not interfere with chemotherapy-induced cell killing in vitro.43
Metastatic traits (cells, mice) In triple-negative and HER2-positive breast cancer lines, MitoQ inhibited every metastatic trait tested.7 In pancreatic cancer it cut lung homing in a short-term mouse assay by about 50% at doses the authors describe as compatible with human treatment.13
Doxorubicin-induced migration (cells, mice) Subcytotoxic doxorubicin raised mitochondrial ROS and promoted migration and invasion. Mitochondria-targeted antioxidants prevented this without impairing doxorubicin cytotoxicity. MitoTEMPO, not MitoQ, prevented metastasis in mice, and doxorubicin alone did not promote metastasis in immunocompetent animals.44
Chemo- and immune-resistance in lung cancer (humanised mice) In the Torino study, MitoQ made tumours grown in humanised mice (mice with human immune cells) more sensitive to chemotherapy and immune killing by disrupting the ROS, HIF-1α and C/EBP-β LAP cascade. The patient arm showed an association only.16
Combination with targeted drugs (cells, mice, two patients) At the Medical College of Wisconsin, the RET inhibitor selpercatinib and the EGFR inhibitor erlotinib raised tumour-cell mitochondrial membrane potential, which increased MitoQ uptake. Each combination suppressed tumour cells and xenografts more than either drug alone, and selpercatinib plus MitoQ prolonged survival in mice. Here MitoQ acts as a cytotoxic agent, not an antioxidant.45,46
Mitophagy in cancer cells A conference abstract from the US Food and Drug Administration reported that triphenylphosphonium agents caused depolarisation and mitophagy more in MDA-MB-231 breast cancer cells than in non-cancerous MCF-12A cells, and that MitoQ-treated rat xenografts accumulated PINK1. This is an abstract, not a peer-reviewed paper.47
ROS-dependent anticancer drugs (glioblastoma cells) Researchers at Army Medical University found that cyclovirobuxine D killed glioblastoma cells through mitochondrial ROS, and that pretreatment with MitoQ or N-acetylcysteine reverted the apoptosis. MitoQ was a tool here, not the study subject, but the result shows that an antioxidant can blunt a ROS-dependent anticancer drug.48

Read together, these studies point in three directions: protection of healthy tissue, modification of tumour behaviour through respiration and metastasis signalling, and combination with targeted drugs. They also show why caution is needed. Depending on concentration, drug partner and oxygenation, the same compound has protected normal cells, sensitised hypoxic tumours, blunted a ROS-dependent anticancer drug and killed tumour cells outright.

The one human report is small. In the Wisconsin thyroid study, two patients with RET-altered thyroid cancer who could not tolerate full-dose selpercatinib were given a reduced selpercatinib dose with MitoQ. Both showed tumour reduction, and one had a markedly better quality of life for a year until the tumour relapsed.⁴⁵ With two patients, no control arm and a targeted drug as the partner, it supports designing studies, not drawing clinical conclusions.

Research opportunities for Mitoquinol

To our knowledge, Mitoquinol has not yet been tested in controlled studies of people receiving or recovering from cancer treatment. The preclinical work raises important questions:

  • Does it protect against anthracycline vascular injury?

  • How much does its timing relative to chemotherapy or radiotherapy matter?

  • Can it support muscle and energy recovery?

  • How might it be combined with targeted drugs?

Because it may affect both healthy tissue and tumour biology, each question needs oncology input and careful design.

Researching this area? Talk to MCRP

MCRP exists to grow this field. If you are planning a cell, animal or human study related to these questions, or you are early in your research career and looking for a starting point, we would like to hear from you.

Contact: mcrp@mitoq.com

Key Takeaways

  • Tumours rewire and exploit mitochondria for energy, spread, oxygen use, survival and immune control, so the organelle sits on both sides of treatment.¹,²

  • Chemotherapy and radiotherapy disrupt mitochondrial function in preclinical models, and small human studies show lower muscle mitochondrial content during chemotherapy.³,⁴,²⁰

  • Fatigue, exercise intolerance, neuropathy and cognitive change are multifactorial and non-specific, so established causes should be excluded first.

  • Individualised exercise is the best-supported recovery strategy.⁹

  • Mitoquinol has shown protective, radiosensitising and anti-metastatic effects in cell and animal models, with one two-patient report in thyroid cancer. Controlled testing in people is an open opportunity for researchers.¹⁴,⁴⁵

  • Because Mitoquinol’s effects depend on drug partner and context, supplement use during cancer treatment should involve the oncology team.⁴⁵,⁴⁸

Educational information only. This article does not recommend starting, stopping or changing cancer treatment, medicines or supplements. Please discuss these decisions with the treating oncology team.

References

  1. Gomez-Duran A, Martínez-Reyes I. Mitochondria as central regulators of cancer progression and antitumor immunity. Trends Endocrinol Metab. 2026. doi:10.1016/j.tem.2026.07.005.

  2. Du H, et al. Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct Target Ther. 2025. doi:10.1038/s41392-025-02311-x.

  3. Li Y, Ding N, Liu X, et al. The disrupted mitochondrial quality control network: a unifying mechanism and therapeutic target for chemotherapy-induced multi-organ toxicity. Biology (Basel). 2026;15(3):230. doi:10.3390/biology15030230.

  4. Mallard J, Hucteau E, Charles AL, et al. Chemotherapy impairs skeletal muscle mitochondrial homeostasis in early breast cancer patients. J Cachexia Sarcopenia Muscle. 2022;13(3):1896-1907. doi:10.1002/jcsm.12991.

  5. Guo J, Xin Q, Liu Z, et al. Mitochondria-targeted strategies in cancer radiotherapy: from ROS regulation to immunogenic cell death. Front Cell Dev Biol. 2026;14:1861854. doi:10.3389/fcell.2026.1861854.

  6. Chiu H-Y, et al. Mitochondrial dysfunction at the center of cancer therapy. Antioxid Redox Signal. 2020. doi:10.1089/ars.2019.7898.

  7. Capeloa T, Krzystyniak J, d’Hose D, et al. MitoQ inhibits human breast cancer cell migration, invasion and clonogenicity. Cancers (Basel). 2022;14(6):1516. doi:10.3390/cancers14061516.

  8. Dominic A, Hamilton D, Abe J. Mitochondria and chronic effects of cancer therapeutics: the clinical implications. J Thromb Thrombolysis. 2021;51(4):884-889. doi:10.1007/s11239-020-02313-2.

  9. LaVoy ECP, Fagundes CP, Dantzer R. Exercise, inflammation, and fatigue in cancer survivors. Exerc Immunol Rev. 2016;22:82-93.

  10. Zong Y, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:124. doi:10.1038/s41392-024-01839-8.

  11. Cheng G, Karoui H, Hardy M, Kalyanaraman B. Redox-crippled MitoQ potently inhibits breast cancer and glioma cell proliferation: a negative control for verifying the antioxidant mechanism of MitoQ in cancer and other oxidative pathologies. Free Radic Biol Med. 2023;205:175-187. doi:10.1016/j.freeradbiomed.2023.06.009.

  12. Cheng G, Zielonka J, Dranka BP, et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 2012;72(10):2634-2644. doi:10.1158/0008-5472.CAN-11-3928.

  13. Capeloa T, Van de Velde JA, d’Hose D, et al. Inhibition of mitochondrial redox signaling with MitoQ prevents metastasis of human pancreatic cancer in mice. Cancers (Basel). 2022;14(19):4918. doi:10.3390/cancers14194918.

  14. Rondeau JD, Lipari S, Mathieu B, et al. Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption. Cell Death Discov. 2024;10:514. doi:10.1038/s41420-024-02277-9.

  15. Che H, Li ZJ, Xu L, Du YB, Zhang SO, Ying XJ. Advances in mitochondrial-targeted colorectal cancer therapy: mechanistic insights and clinical translation. iScience. 2025;29(2):114511. doi:10.1016/j.isci.2025.114511.

  16. Salaroglio IC, Belisario DC, Akman M, et al. Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer. J Exp Clin Cancer Res. 2022;41:243. doi:10.1186/s13046-022-02447-6.

  17. Zhong H, Pan R, Ouyang Y, et al. Targeting mitochondrial homeostasis as a cancer treatment strategy: current status and future prospects. Mol Cancer. 2026;25(1):38. doi:10.1186/s12943-026-02571-3.

  18. Clayton ZS, Brunt VE, Hutton DA, et al. Doxorubicin-induced oxidative stress and endothelial dysfunction in conduit arteries is prevented by mitochondrial-specific antioxidant treatment. JACC CardioOncol. 2020;2(3):475-488. doi:10.1016/j.jaccao.2020.06.010.

  19. Canta A, Pozzi E, Carozzi VA. Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). Toxics. 2015;3(2):198-223. doi:10.3390/toxics3020198.

  20. Mallard J, Hucteau E, Bender L, et al. A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients. J Cachexia Sarcopenia Muscle. 2024;15(1):292-305. doi:10.1002/jcsm.13414.

  21. Mallard J, Hucteau E, Somme L, et al. Impairments in mitochondrial dynamics and morphology in skeletal muscle of breast cancer patients after a single paclitaxel administration. Exp Physiol. 2026. doi:10.1113/EP093922.

  22. Guigni BA, Callahan DM, Tourville TW, et al. Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am J Physiol Cell Physiol. 2018;315(5):C744-C756. doi:10.1152/ajpcell.00002.2018.

  23. Chen J, Chu X, Wu Y, et al. Mechanistic insights and therapeutic interventions of mitochondrial quality control in chemotherapy-related cognitive impairment. Neoplasia. 2026;74:101291. doi:10.1016/j.neo.2026.101291.

  24. Gan L, Wang Z, Si J, et al. Protective effect of mitochondrial-targeted antioxidant MitoQ against iron ion 56Fe radiation induced brain injury in mice. Toxicol Appl Pharmacol. 2018;341:1-7. doi:10.1016/j.taap.2018.01.003.

  25. Yang S, Li Y, Zhang J, Shen A, Hu B, Yan J. The interplay between DNA damage response and mitochondrial dysfunction in radiotherapy. Front Oncol. 2025;15:1642100. doi:10.3389/fonc.2025.1642100.

  26. Sahu K, Langeh U, Singh C, Singh A. Crosstalk between anticancer drugs and mitochondrial functions. Curr Res Pharmacol Drug Discov. 2021;2:100047. doi:10.1016/j.crphar.2021.100047.

  27. Wang T, Xing G, Fu T, et al. Role of mitochondria in doxorubicin-mediated cardiotoxicity: from molecular mechanisms to therapeutic strategies. Int J Med Sci. 2024;21(5):809-816. doi:10.7150/ijms.94485.

  28. Huot JR, Baumfalk D, Resendiz A, Bonetto A, Smuder AJ, Penna F. Targeting mitochondria and oxidative stress in cancer- and chemotherapy-induced muscle wasting. Antioxid Redox Signal. 2023;38(4-6):352-370. doi:10.1089/ars.2022.0149.

  29. Milatovic D, Montine TJ, Aschner M. Measurement of isoprostanes as markers of oxidative stress. Methods Mol Biol. 2011;758:195-204. doi:10.1007/978-1-61779-170-3_13.

  30. Graille M, Wild P, Sauvain JJ, et al. Urinary 8-OHdG as a biomarker for oxidative stress: a systematic literature review and meta-analysis. Int J Mol Sci. 2020;21(11):3743. doi:10.3390/ijms21113743.

  31. Ballarò R, Beltrà M, De Lucia S, et al. Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 2019;33:fj.201801862R. doi:10.1096/fj.201801862R.

  32. Ballarò R, Lopalco P, Audrito V, et al. Targeting mitochondria by SS-31 ameliorates the whole body energy status in cancer- and chemotherapy-induced cachexia. Cancers (Basel). 2021;13(4):850. doi:10.3390/cancers13040850.

  33. Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96-103. doi:10.1111/j.1749-6632.2010.05627.x.

  34. Rossman MJ, Santos-Parker JR, Steward CAC, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71(6):1056-1063. doi:10.1161/HYPERTENSIONAHA.117.10787.

  35. Williamson J, Hughes CM, Cobley JN, Davison GW. The mitochondria-targeted antioxidant MitoQ attenuates exercise-induced mitochondrial DNA damage. Redox Biol. 2020;36:101673. doi:10.1016/j.redox.2020.101673.

  36. Yoon NG, Lee H, Kim SY, et al. Mitoquinone inactivates mitochondrial chaperone TRAP1 by blocking the client binding site. J Am Chem Soc. 2021;143(47):19684-19696. doi:10.1021/jacs.1c07099.

  37. Abdeahad H, Moreno DG, Bloom SI, Norman L, Lesniewski LA, Donato AJ. MitoQ reduces senescence burden in doxorubicin-treated endothelial cells by reducing mitochondrial ROS and DNA damage. Am J Physiol Heart Circ Physiol. 2025;329(5):H1154-H1161. doi:10.1152/ajpheart.00568.2025.

  38. Pin F, Huot JR, Bonetto A. The mitochondria-targeting agent MitoQ improves muscle atrophy, weakness and oxidative metabolism in C26 tumor-bearing mice. Front Cell Dev Biol. 2022;10:861622. doi:10.3389/fcell.2022.861622.

  39. Bao X, Liu X, Wu Q, et al. Mitochondrial-targeted antioxidant MitoQ-mediated autophagy: a novel strategy for precise radiation protection. Antioxidants (Basel). 2023;12(2):453. doi:10.3390/antiox12020453.

  40. Sun C, Liu X, Di C, et al. MitoQ regulates autophagy by inducing a pseudo-mitochondrial membrane potential. Autophagy. 2017;13(4):730-738. doi:10.1080/15548627.2017.1280219.

  41. Lyamzaev KG, Tokarchuk AV, Panteleeva AA, Mulkidjanian AY, Skulachev VP, Chernyak BV. Induction of autophagy by depolarization of mitochondria. Autophagy. 2018;14(5):921-924. doi:10.1080/15548627.2018.1436937.

  42. Ramsey H, Zhang Q, Wu MX. Mitoquinone restores platelet production in irradiation-induced thrombocytopenia. Platelets. 2015;26(5):459-466. doi:10.3109/09537104.2014.935315.

  43. Capeloa T, Krzystyniak J, Canas Rodriguez A, et al. MitoQ prevents human breast cancer recurrence and lung metastasis in mice. Cancers (Basel). 2022;14(6):1488. doi:10.3390/cancers14061488.

  44. Capeloa T, Van de Velde JA, Pranzini E, et al. Mitochondrial ROS inhibition prevents doxorubicin-induced breast cancer cell migration and invasion. iScience. 2025;28(8):113031. doi:10.1016/j.isci.2025.113031.

  45. Chen W, Dream S, Leung PY, Wu PK, Wong S, Park JI. Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer. npj Precis Oncol. 2024;8:39. doi:10.1038/s41698-024-00536-7.

  46. Leung PY, Chen W, Sari AN, et al. Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival. World J Gastroenterol. 2024;30(7):714-727. doi:10.3748/wjg.v30.i7.714.

  47. Biel T, Rao A. Breast cancer cells treated with mitochondria targeted redox active agents induce mitophagy [abstract 1505]. Cancer Res. 2017;77(13 Suppl). doi:10.1158/1538-7445.AM2017-1505.

  48. Zhang L, Fu R, Duan D, et al. Cyclovirobuxine D induces apoptosis and mitochondrial damage in glioblastoma cells through ROS-mediated mitochondrial translocation of cofilin. Front Oncol. 2021;11:656184. doi:10.3389/fonc.2021.656184.